Serplulimab in Patients With Microsatellite Instability–High Solid Tumours
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
Br. J. Cancer 2022 Oct 19;[EPub Ahead of Print], S Qin, J Li, H Zhong, C Jin, L Chen, X Yuan, Q Fan, K Chen, P Cao, J Xiao, D Jiang, T Zhang, H Zhang, X Wang, W Wang, L Han, Q Wang, J ZhuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.